Skip to main content
. Author manuscript; available in PMC: 2016 Mar 25.
Published in final edited form as: Eur Neurol. 2015 Mar 25;73(0):238–246. doi: 10.1159/000377675

Figure 3. B cell development and expression of surface markers targeted by emerging MS therapeutics.

Figure 3

CD19 is a pan-B cell marker expressed on nearly the entire B cell lineage starting from early Pro-B cells and disappearing on long-lived plasma cells; MEDI-551 (anti-CD19 antibody) currently in clinical development for MS therapy cuts deeply into the B cell compartment. CD20 is expressed on the majority of B cells; it appears on Pre B cells and becomes downregulated during terminal differentiation to plasmablasts/plasma cells. Interestingly, CD20 is also expressed by a small subset of T cells, which become depleted by rituximab. BAFF-R has a similar expression pattern as CD20; VAY736 is now also being studied as MS therapy.